The ETFO ELHT Benefits Plan announced in May 2022 that plan members or their dependants using Humira, Enbrel, and Lantus would be required to switch to the corresponding biosimilar effective September 1, 2022, with a transition period to December 1, 2022.   If you still have not made this switch by November 30, 2022, coverage will no longer be available for these three medications effective December 1, 2022. 

Effective September 1, 2022, plan members who are responsible for paying benefit premiums (**plan members with optional or supplemental life and/or part-time members with health and dental coverage) will now have premium deductions done by pre-authorized deductions (PAD) instead of via payroll deduction.  Those plan members** that have still not provided bank information to OTIP by November 30, 2022 will have applicable benefits terminated on December 1, 2022.

The ETFO ELHT Benefits Plan renews effective September 1 of each year. September 1, 2022 is the fifth renewal of our benefits plan.  A renewal notice was emailed to plan members on May 18, 2022. Information includes new renewal rates for health and dental coverage, administrative plan/administrative changes (including proton pump inhibitors/PPI, biosimilar switch, direct withdrawals) to the plans, and notice about the September 22, 2022 Annual Plan Member Meeting.